Product Information

IRBESARTAN 300 MG TABLET is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.1647 per EA under NDC 31722073130. Its NADAC has been published 677 times since Nov 28, 2013.

FDA first approved this application on Sep 27, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

IRBESARTAN 300 MG TABLET

Irbesartan
$0.1647per EA

Strength

300 mg/1

NDC

31722073130

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

IRBESARTAN

Approval Type

Generic (ANDA)

FDA Application

ANDA202910

FDA Approved

9/27/2012

TE Code

AB

On Market Since

9/27/2012

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker

Price Statistics

The NADAC for IRBESARTAN 300 MG TABLET has been published 677 times since Nov 28, 2013, and over the history we have for it it has declined 53.0%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1647 per EA
All-time high$0.3794 (Jun 10, 2020)
All-time low$0.1461 (Feb 18, 2026)
52-week high$0.1647
52-week low$0.1461
Median price$0.2660
Average price$0.2605
Largest weekly change+33.1% (Aug 21, 2024)
Weeks tracked677
Tracking sinceNov 28, 2013

Price History

1W

0.0%

1M

+1.5%

3M

+5.9%

6M

+7.8%

1Y

+7.2%

3Y

-9.8%

5Y

-43.5%

All

-53.0%

Generic Alternatives

The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of IRBESARTAN 300 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN 300 MG TABLET, manufactured by Camber Pharmaceuticals Inc., is $0.1647 per EA (NDC 31722073130), effective Nov 11, 2026.

How has the price of IRBESARTAN 300 MG TABLET changed over time?

Over the history we have for it, the NADAC for IRBESARTAN 300 MG TABLET has declined 53.0%. It has been tracked across 677 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for IRBESARTAN 300 MG TABLET?

Since Nov 28, 2013, the NADAC for IRBESARTAN 300 MG TABLET has ranged from a low of $0.1461 (Feb 18, 2026) to a high of $0.3794 (Jun 10, 2020), with a median of $0.2660 per EA.

Are there cheaper alternatives to IRBESARTAN 300 MG TABLET?

Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IRBESARTAN 300 MG TABLET, is $0.1555 per EA — about 6% below IRBESARTAN 300 MG TABLET.

Who manufactures IRBESARTAN 300 MG TABLET?

IRBESARTAN 300 MG TABLET (NDC 31722073130) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.